Recursion Pharmaceuticals is acquiring two Canada-based artificial intelligence startups, Cyclica and Valence. The “biology-first company” says both deals build up its capability to apply AI to the chemistry side of drug discovery.
Ampersand Biomedicines emerged from stealth with technology for site-specific drug delivery that avoids toxic effects throughout the body. The Flagship Pioneering-founded startup is backed by $50 million in financing.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Despite challenging financial market conditions, clinical-stage Structure Therapeutics was able to upsize its IPO. Much of the new cash will support its lead program, an oral small molecule that could weigh in on the diabetes and obesity indications currently dominated by blockbuster injectable medicines.
Atomic AI combines artificial intelligence analysis with wet lab experiments to discover small molecules capable of drugging RNA. The startup, based on technology initially developed at Stanford, is backed by a $35 million Series A round of financing.
A collaboration between Nvidia and startup Evozyne was able to produce novel versions of a human protein never before seen in nature but with enhanced function and the same safety as native protein. The research lays the groundwork for potential new therapies for a rare inherited disorder.
Versant Ventures-backed Belharra Therapeutics has launched with $130 million in funding and a partnership with Roche subsidiary Genentech. The startup’s technology analyzes proteins in the context of the entire cell, enabling it to discover molecules that bind to targets previously deemed undruggable.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.
Risk-based quality management is a data monitoring approach that accelerates the drug development pathway without compromising on safety – and one that is enhanced by the use of technologies such as artificial intelligence.
GSK is making greater use of artificial intelligence and computational techniques as part of its drug discovery efforts. Speaking during the HLTH conference in Las Vegas, executive Mike Montello likened his company's techniques to the efforts to study and analyze images from outer space.
Juvena Therapeutics is developing secreted protein drugs built on new knowledge gleaned from proprietary technology that maps these proteins and the tissues in the body where they offer a regenerative effect. The startup’s lead program is in development for the muscle disorder myotonic dystrophy type 1.
Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress.
Odyssey Therapeutics raised $168 million in Series B financing, the largest round of funding for a biotech startup this week. Companies developing new technologies in genetic diseases, cancer, and drug research are represented also represented in this week’s recap of life science financings.
Artificial intelligence and machine learning are key to 3T Biosciences’ approach to identifying novel drug targets and engineering better, safer cancer immunotherapies. The Stanford spinout is now out of stealth with a $40 million Series A financing and a plan to reach the clinic within two years.
Bristol Myers Squibb’s drug R&D includes targeted protein degradation, an approach that can require proteins that don’t normally interact to find a way to stick together. BMS is turning to startup A-Alpha Bio to discover “molecular glues” that can accomplish the task.
Merck is paying $25 million to kick off a research partnership with Cerevance, a startup that analyzes donor brain tissue to find novel targets for new neurological disorder drugs. While Cerevance’s lead program is a Parkinson’s disease drug, Merck wants to see if the startup’s technology can help it discover and develop new Alzheimer’s disease drugs.
Decentralized clinical trials, drug discovery technologies, and partnering strategies between big pharma and startups were among the topics covered during INVEST PharmaTech, a virtual event hosted this week by MedCity News.